Corrections and removals
This article was originally published in The Gray Sheet
Executive Summary
Effective date of FDA's direct-to-final rule eliminating reporting requirements for distributors is delayed until Feb. 22, 1999. Originally scheduled to take effect Dec. 21, implementation of the reg is being postponed because FDA "has not yet received approval under the Paperwork Reduction Act" from the Office of Management and Budget for the reg's information collection requirements, FDA explains in the Nov. 18 Federal Register. FDA first published the rule, which the agency says received no significant adverse comment, in August ("The Gray Sheet" Aug. 10, In Brief)
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.